Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial
CONCLUSIONS: In high-risk thrombosis patients with a history of prior revascularisation, rivaroxaban monotherapy versus combination therapy demonstrated favourable safety and efficacy outcomes.PMID:38562065 | PMC:PMC10979387 | DOI:10.4244/EIJ-D-23-00396
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Authors: Takashi Noda Kotaro Nochioka Koichi Kaikita Masaharu Akao Junya Ako Tetsuya Matoba Masato Nakamura Katsumi Miyauchi Nobuhisa Hagiwara Kazuo Kimura Atsushi Hirayama Kunihiko Matsui Hisao Ogawa Satoshi Yasuda On Behalf Of The Afire Investigators Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiovascular & Thoracic Surgery | Heart Attack | Ischemic Stroke | Stroke | Thrombosis